← back to search

Andrea Antinori

Istituto Nazionale per l'Assicurazione Contro gli Infortuni sul Lavoro · IT
Area of research
Infectious Diseases · Virology
Research interest
Research interests include HIV/AIDS drug development and treatment, HIV Research and Treatment, HIV/AIDS Research and Interventions, and HIV-related health complications and treatments.
h-index
86
citations
37,143
works
1,089
NIH funding
primary concept
Medicine
email

Recent publications

Care interruptions and mortality among adults in Europe and North America
AIDS 2024cited by 11position: middledoi
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
The Lancet HIV 2023cited by 68position: middledoi
Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox Vaccination
Vaccines 2023cited by 33position: middledoi
Pillars of long-term antiretroviral therapy success
Pharmacological Research 2023cited by 20position: middledoi
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
New England Journal of Medicine 2022cited by 2,124position: middledoi
Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study
Journal of Global Antimicrobial Resistance 2022cited by 31position: middledoi
SARS-CoV-2 Specific Immune Response and Inflammatory Profile in Advanced HIV-Infected Persons during a COVID-19 Outbreak
Viruses 2022cited by 16position: middledoi
The role of Lung Ultrasound in the diagnosis of SARS-COV-2 disease in pregnant women
Journal of Ultrasound 2022cited by 2position: middledoi
Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study
eLife 2021cited by 210position: middledoi
Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study
Thrombosis and Haemostasis 2021cited by 141position: middledoi
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients
Genes and Immunity 2021cited by 76position: middledoi
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males
EBioMedicine 2021cited by 64position: middledoi
The unbalanced p53/SIRT1 axis may impact lymphocyte homeostasis in COVID-19 patients
International Journal of Infectious Diseases 2021cited by 50position: middledoi
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity
Human Genetics 2021cited by 39position: middledoi
GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults
Science Translational Medicine 2021cited by 31position: middledoi
Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study
Frontiers in Medicine 2021cited by 29position: middledoi
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population
European Journal of Human Genetics 2020cited by 270position: middledoi
Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19)
Cell Death and Differentiation 2020cited by 243position: middledoi
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study
Nutrition Metabolism and Cardiovascular Diseases 2020cited by 191position: middledoi
Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome
Cell Death and Disease 2020cited by 117position: middledoi
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study
European Journal of Internal Medicine 2020cited by 112position: middledoi
An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019
Clinical Infectious Diseases 2020cited by 108position: middledoi
COVID-19 disease—Temporal analyses of complete blood count parameters over course of illness, and relationship to patient demographics and management outcomes in survivors and non-survivors: A longitudinal descriptive cohort study
PLoS ONE 2020cited by 66position: middledoi
COVID‐19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS‐CoV‐2
Journal of Medical Virology 2020cited by 58position: lastdoi
RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies
Vascular Pharmacology 2020cited by 50position: middledoi
Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE
Clinical Infectious Diseases 2020cited by 21position: middledoi
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
The Lancet 2019cited by 990position: middledoi
Defining cerebrospinal fluid HIV RNA escape
AIDS 2019cited by 56position: middledoi
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy
Journal of Antimicrobial Chemotherapy 2019cited by 24position: middledoi
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients
PLoS ONE 2018cited by 20position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 6 papers (2020–2023)Enrico Girardi · University of Rome Tor Vergata6 papers (2017–2023)Markus Maeurer · Jena University Hospital6 papers (2020–2022)Chiara Agrati · Center for Prevention and Treatment of Infections6 papers (2020–2022)Emanuele Nicastri · Thriasio General Hospital of Elefsina5 papers (2020–2023)Giuseppe Ippolito · University of Michigan5 papers (2020–2021)Maria Rosaria Capobianchi · Istituti di Ricovero e Cura a Carattere Scientifico5 papers (2020–2021) · 5 papers (2020–2023)Alimuddin Zumla · Semmelweis University4 papers (2020–2021) · 4 papers (2020–2021)Stefania Notari · Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani4 papers (2020–2022)Franco Locatelli · Assistance Publique – Hôpitaux de Paris4 papers (2020–2021)Rita Casetti · Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani4 papers (2020–2021)Nicola Petrosillo · Campus Bio Medico University Hospital3 papers (2020–2020)Giulia Matusali · Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani3 papers (2020–2023)Antonella d’Arminio Monforte · Check Point (Israel)3 papers (2012–2018) · 3 papers (2020–2020) · 3 papers (2020–2021) · 3 papers (2020–2023)Germana Grassi · Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani3 papers (2020–2021)